{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T01:01:45Z","timestamp":1771549305379,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fondazione Cassa di Risparmio Bologna","award":["2019.0547"],"award-info":[{"award-number":["2019.0547"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-37774-7","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:36:48Z","timestamp":1770107808000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and exploratory functional effects of topical cord blood serum in glaucoma patients"],"prefix":"10.1038","volume":"16","author":[{"given":"Enrico","family":"Lupardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Odorici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Buzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Bergantin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Bisti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Polizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piera","family":"Versura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"37774_CR1","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.3390\/cells12242797","volume":"12","author":"K. M. Feng","year":"2023","unstructured":"Feng, K. M., Tsung, T. H., Chen, Y. H. & Lu, D. W. The role of retinal ganglion cell structure and function in glaucoma. Cells 12, 2797 (2023).","journal-title":"Cells"},{"issue":"10","key":"37774_CR2","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A. et al. Reduction of intraocular pressure and glaucoma progression: Results from the early manifest glaucoma trial. Arch. Ophthalmol. 120(10), 1268\u20131279 (2002).","journal-title":"Arch. Ophthalmol."},{"key":"37774_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/00055735-200404000-00008","volume":"15","author":"MC Leske","year":"2004","unstructured":"Leske, M. C., Heijl, A., Hyman, L., Bengtsson, B. & Komaroff, E. Factors for progression and glaucoma treatment: the early manifest glaucoma trial. Curr. Opin. Ophthalmol. 15, 102\u2013106 (2004).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"37774_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S1388-2457(00)00525-3","volume":"112","author":"V Parisi","year":"2001","unstructured":"Parisi, V. Impaired visual function in glaucoma. Clin. Neurophysiol. 112, 351\u2013358 (2001).","journal-title":"Clin. Neurophysiol."},{"key":"37774_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ophtha.2005.10.044","volume":"113","author":"V Parisi","year":"2006","unstructured":"Parisi, V., Miglior, S., Manni, G., Centofanti, M. & Bucci, M. G. Clinical ability of pattern electroretinograms and visual evoked potentials in detecting visual dysfunction in ocular hypertension and glaucoma. Ophthalmology 113, 216\u2013228 (2006).","journal-title":"Ophthalmology"},{"key":"37774_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/ICU.0000000000001016","volume":"35","author":"EC Ciociola","year":"2024","unstructured":"Ciociola, E. C., Fernandez, E., Kaufmann, M. & Klifto, M. R. Future directions of glaucoma treatment: emerging gene, neuroprotection, nanomedicine, stem cell, and vascular therapies. Curr. Opin. Ophthalmol. 35, 89 (2024).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"37774_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pharmthera.2013.01.004","volume":"138","author":"SJ Allen","year":"2013","unstructured":"Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U. & Patel, N. K. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol. Ther. 138, 155\u2013175 (2013).","journal-title":"Pharmacol. Ther."},{"key":"37774_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000514441","volume":"64","author":"E Fudalej","year":"2021","unstructured":"Fudalej, E. et al. Neuroprotective factors of the retina and their role in promoting survival of retinal ganglion cells: A review. Ophthalmic Res. 64, 345\u2013355 (2021).","journal-title":"Ophthalmic Res."},{"key":"37774_CR9","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1523\/JNEUROSCI.09-04-01263.1989","volume":"9","author":"G Carmignoto","year":"1989","unstructured":"Carmignoto, G., Maffei, L., Candeo, P., Canella, R. & Comelli, C. Effect of NGF on the survival of rat retinal ganglion cells following optic nerve section. J. Neurosci. 9, 1263\u20131272 (1989).","journal-title":"J. Neurosci."},{"key":"37774_CR10","first-page":"3232","volume":"34","author":"R Siliprandi","year":"1993","unstructured":"Siliprandi, R., Canella, R. & Carmignoto, G. Nerve growth factor promotes functional recovery of retinal ganglion cells after ischemia. Invest. Ophthalmol. Vis. Sci. 34, 3232\u20133245 (1993).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"37774_CR11","doi-asserted-by":"publisher","first-page":"13469","DOI":"10.1073\/pnas.0906678106","volume":"106","author":"A Lambiase","year":"2009","unstructured":"Lambiase, A. et al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: implications for glaucoma. Proc. Natl. Acad. Sci. U S A. 106, 13469\u201313474 (2009).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"37774_CR12","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1146\/annurev.neuro.24.1.1217","volume":"24","author":"MV Sofroniew","year":"2001","unstructured":"Sofroniew, M. V., Howe, C. L. & Mobley, W. C. Nerve growth factor signaling, neuroprotection, and neural repair. Annu. Rev. Neurosci. 24, 1217\u20131281 (2001).","journal-title":"Annu. Rev. Neurosci."},{"key":"37774_CR13","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1167\/iovs.16-19825","volume":"57","author":"L Feng","year":"2016","unstructured":"Feng, L. et al. Long-Term protection of retinal ganglion cells and visual function by Brain-Derived neurotrophic factor in mice with ocular hypertension. Invest. Ophthalmol. Vis. Sci. 57, 3793\u20133802 (2016).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"37774_CR14","doi-asserted-by":"publisher","first-page":"e115579","DOI":"10.1371\/journal.pone.0115579","volume":"9","author":"L Domenici","year":"2014","unstructured":"Domenici, L. et al. Rescue of retinal function by BDNF in a mouse model of glaucoma. PLoS ONE. 9, e115579 (2014).","journal-title":"PLoS ONE"},{"key":"37774_CR15","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3390\/biom10050678","volume":"10","author":"S. Di Marco","year":"2020","unstructured":"Di Marco, S. et al. Cord blood serum (CBS)-Based eye drops modulate light-induced neurodegeneration in albino rat retinas. Biomolecules 10, 678 (2020).","journal-title":"Biomolecules"},{"key":"37774_CR16","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1080\/02713683.2017.1279634","volume":"42","author":"M Sacchetti","year":"2017","unstructured":"Sacchetti, M. et al. Recombinant human nerve growth factor treatment promotes photoreceptor survival in the retinas of rats with retinitis pigmentosa. Curr. Eye Res. 42, 1064\u20131068 (2017).","journal-title":"Curr. Eye Res."},{"key":"37774_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.transci.2018.06.001","volume":"57","author":"M Buzzi","year":"2018","unstructured":"Buzzi, M. et al. Comparison of growth factor and interleukin content of adult peripheral blood and cord blood serum eye drops for cornea and ocular surface diseases. Transfus. Apher Sci. 57, 549\u2013555 (2018).","journal-title":"Transfus. Apher Sci."},{"key":"37774_CR18","doi-asserted-by":"publisher","first-page":"e0234145","DOI":"10.1371\/journal.pone.0234145","volume":"15","author":"C Ciavarella","year":"2020","unstructured":"Ciavarella, C. et al. Effects of cord blood serum (CBS) on viability of retinal M\u00fcller glial cells under in vitro injury. PLoS ONE. 15, e0234145 (2020).","journal-title":"PLoS ONE"},{"key":"37774_CR19","first-page":"213","volume":"20","author":"S Valente","year":"2022","unstructured":"Valente, S. et al. Impact of blood source and component manufacturing on neurotrophin content and in vitro cell wound healing. Blood Transfus. 20, 213\u2013222 (2022).","journal-title":"Blood Transfus."},{"key":"37774_CR20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/ICO.0b013e3182580762","volume":"32","author":"P Versura","year":"2013","unstructured":"Versura, P. et al. Efficacy of standardized and quality-controlled cord blood serum eye drop therapy in the healing of severe corneal epithelial damage in dry eye. Cornea 32, 412\u2013418 (2013).","journal-title":"Cornea"},{"key":"37774_CR21","first-page":"145","volume":"14","author":"P Versura","year":"2016","unstructured":"Versura, P. et al. Targeting growth factor supply in keratopathy treatment: Comparison between maternal peripheral blood and cord blood as sources for the preparation of topical eye drops. Blood Transfus. 14, 145\u2013151 (2016).","journal-title":"Blood Transfus."},{"key":"37774_CR22","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/ICO.0000000000001257","volume":"36","author":"G Giannaccare","year":"2017","unstructured":"Giannaccare, G., Buzzi, M., Fresina, M., Velati, C. & Versura, P. Efficacy of 2-Month treatment with cord blood serum eye drops in ocular surface disease: an in vivo confocal microscopy study. Cornea 36, 915 (2017).","journal-title":"Cornea"},{"key":"37774_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40123-020-00239-9","volume":"9","author":"G Giannaccare","year":"2020","unstructured":"Giannaccare, G., Carnevali, A., Senni, C., Logozzo, L. & Scorcia, V. Umbilical cord blood and serum for the treatment of ocular diseases: A comprehensive review. Ophthalmol. Ther. 9, 235\u2013248 (2020).","journal-title":"Ophthalmol. Ther."},{"key":"37774_CR24","doi-asserted-by":"publisher","first-page":"100476","DOI":"10.1016\/j.xops.2024.100476","volume":"4","author":"S Rizzo","year":"2024","unstructured":"Rizzo, S. et al. Safety results for geographic atrophy associated with age-related macular degeneration using subretinal cord blood platelet-rich plasma. Ophthalmol. Sci. 4, 100476 (2024).","journal-title":"Ophthalmol. Sci."},{"key":"37774_CR25","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1097\/ICO.0b013e31820d850f","volume":"30","author":"KC Yoon","year":"2011","unstructured":"Yoon, K. C., Choi, W., You, I. C. & Choi, J. Application of umbilical cord serum Eyedrops for recurrent corneal erosions. Cornea 30, 744\u2013748 (2011).","journal-title":"Cornea"},{"key":"37774_CR26","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3390\/jcm8091478","volume":"8","author":"F Bernabei","year":"2019","unstructured":"Bernabei, F. et al. Blood-Based treatments for severe dry eye disease: the need of a consensus. J. Clin. Med. 8, 1478 (2019).","journal-title":"J. Clin. Med."},{"key":"37774_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-314859","author":"E Campos","year":"2019","unstructured":"Campos, E. et al. Blood derived treatment from two allogeneic sources for severe dry eye associated to keratopathy: a multicentre randomised cross over clinical trial. Br. J. Ophthalmol. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314859 (2019).","journal-title":"Br. J. Ophthalmol."},{"key":"37774_CR28","first-page":"2381296","volume":"2018","author":"E. Campos","year":"2018","unstructured":"Campos, E. et al. Topical treatment with cord blood serum in glaucoma patients: A preliminary report. Case Rep. Ophthalmol. Med. 2018, 2381296 (2018).","journal-title":"Case Rep. Ophthalmol. Med."},{"key":"37774_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2017.03.029","volume":"1665","author":"H Zhao","year":"2017","unstructured":"Zhao, H. et al. Molecular mechanisms of brain-derived neurotrophic factor in neuro-protection: recent developments. Brain Res. 1665, 1\u201321 (2017).","journal-title":"Brain Res."},{"key":"37774_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/tvst.4.6.1","volume":"4","author":"E Cerri","year":"2015","unstructured":"Cerri, E. et al. Conjunctivally applied BDNF protects photoreceptors from light-induced damage. Transl Vis. Sci. Technol. 4, 1 (2015).","journal-title":"Transl Vis. Sci. Technol."},{"key":"37774_CR31","doi-asserted-by":"publisher","first-page":"875662","DOI":"10.3389\/fphar.2022.875662","volume":"13","author":"L Lambuk","year":"2022","unstructured":"Lambuk, L. et al. Brain-derived neurotrophic factor-mediated neuroprotection in glaucoma: A review of current state of the art. Front. Pharmacol. 13, 875662 (2022).","journal-title":"Front. Pharmacol."},{"key":"37774_CR32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1080\/02713683.2017.1396617","volume":"43","author":"AA Shpak","year":"2018","unstructured":"Shpak, A. A., Guekht, A. B., Druzhkova, T. A., Kozlova, K. I. & Gulyaeva, N. V. Brain-derived neurotrophic factor in patients with primary open-angle glaucoma and age-related cataract. Curr. Eye Res. 43, 224\u2013231 (2018).","journal-title":"Curr. Eye Res."},{"key":"37774_CR33","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.ophtha.2018.02.022","volume":"125","author":"S Bonini","year":"2018","unstructured":"Bonini, S. et al. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology 125, 1332\u20131343 (2018).","journal-title":"Ophthalmology"},{"key":"37774_CR34","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ajo.2021.11.002","volume":"234","author":"G Beykin","year":"2022","unstructured":"Beykin, G. et al. Phase 1b randomized controlled study of short course topical recombinant human nerve growth factor (rhNGF) for neuroenhancement in glaucoma: Safety, tolerability, and efficacy measure outcomes. Am. J. Ophthalmol. 234, 223\u2013234 (2022).","journal-title":"Am. J. Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37774-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37774-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37774-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:05:14Z","timestamp":1771545914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37774-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["37774"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-37774-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A patent, \u201cBlood serum for use in the treatment of neurodegenerative ophthalmologic pathologies\u201d, covering the topic of this manuscript, was filed on 15\/06\/2017 and is owned by University of Bologna, IRCCS AOU BO and University of L\u2019Aquila. P.V., M.B., and S.B. are among the inventors of the patent and participated to this research without any commercial involvement. The other Authors of the manuscript have no competing interest in the issue of the present manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7033"}}